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Background: PCR-based diagnostic procedures are not able to characterise 6% of CF alleles. Recently, the application of array-CGH and of CFTR
mRNA analysis has allowed the identification of new copy number mutations and splicing defects, that account for 2% and 13% of CF alleles,
respectively, in the Italian population.
Methods: Here, we report the characterisation of a large duplication in CFTR gene through different methods: MLPA assay, RT-PCR and high-
resolution array-CGH.
Results: We identified a large duplication, involving exons 6b–16, in a patient heterozygous for F508del mutation. This duplication produces an
abnormal transcript with an out of frame addition of 2244 nucleotides and leads to the insertion of 8 amino-acid residues in the protein, followed
by a stop codon.
Conclusions: We propose a wide methodological approach based on MLPA assay, RT-PCR and high-resolution array-CGH to routinely analyse
CF patients uncharacterised for one or both CFTR alleles.
© 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: CFTR; mRNA; Duplication; Array-CGH1. Introduction
Cystic fibrosis (CF; MIM 219700) is the most frequent
severe autosomal recessive disorder in the European population.
In the Italian population, it affects about one in 3100 births, and
approximately, one in 30 individuals are heterozygous [1].
Mutations in the CF transmembrane conductance regulator gene
(CFTR/ABCC7; MIM 602421) induce a wide spectrum of
clinical phenotypes from classic CF to milder forms of the
disease [2]. To date, more than 1800 different CFTR gene
defects have been deposited in the CF Mutation Database☆ Conflict of interest: the authors declare that there is no conflict of interest.
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Ca' Granda Ospedale Maggiore Policlinico, Via Commenda, 12, 20122 Milan,
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1569-1993/$ - see front matter © 2011 European Cystic Fibrosis Society. Publishe
doi:10.1016/j.jcf.2011.06.007(Cystic Fibrosis Mutation Database, http://www.genet.sickkids.
on.ca/cftr/app). The vast majority of these mutant alleles are
either single base-pair substitutions or microinsertion/deletions.
A three base-pair deletion in exon 10, which results in a loss of a
phenylalanine at amino acid position 508 (c.1521_1523delCTT,
F508del), accounts for about two thirds of all CFTR mutations
worldwide [3,4].
Although in the majority of CF patients, mutations have been
defined by common polymerase chain reaction (PCR)-based
techniques, including direct sequencing and denaturing high-
performance liquid chromatography (DHPLC), a number of
cases still remain uncharacterised.
At the present time, different methods (MLPA; QFM-PCR)
could identify large DNA rearrangements in the CFTR gene [5]
and recently, high resolution array-CGH has been demonstrated
to be an efficient method for detecting both intragenic deletions
and duplications. Owing to the extremely high probe densityd by Elsevier B.V. All rights reserved.
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be immediately and very precisely localised, greatly facilitating
the task of breakpoint characterisation at the DNA sequence
level [6].
This work describes the detection of a large duplication in
the CFTR gene encompassing exons 6b to 16, identified for the
first time in the Italian population and previously submitted
to CF Mutation Database by Pepermans et al. ( cDNA Name:
c.(?_744)_(2988_?)dup).
2. Materials and methods
2.1. Patient
The patient is a one year old Caucasian female selected by
neonatal screening programme (blood immunoreactive trypsin-
ogen collected at 48th–120th hours was 81 ng/dl and between
20–30 days was 149 ng/dl), and diagnosed as having CF by
repeated positive sweat chloride test (116 mmol/l, 106 mmol/l).
DNA analysis showed F508del on one allele. When first seen
at the CF Center at the age of 4 weeks, she had signs and
symptoms of pancreatic insufficiency. Faecal elastase was
b15 μg/g faeces. Of note, her father's sister had died in the lateFig. 1. Analysis of the cDNA and genomic structure;
A). Schematic representation of the duplicated region, where duplicated exons are r
B). CFTRdup6b-16 cDNA analysis. The 2166 bp PCR product obtained using primer
L, ladder; lane 1: Cf parent with the duplication; lane 2: wild type sample. The ladd
C). Sequencing of the 2166 bp fragment with the reverse primer B15R, located on e
(exon 6B) and the wild type exons 15–16.1960s of undefined pulmonary disease, at the age of 18 months.
During follow up, she had recurrent respiratory infections,
but her growth was regular along the 10th weight for height
percentile.
2.2. DNA analysis
DNA was extracted from blood, using a semi-automated
extractor (Quick-Gene-810 Fujifilm, Tokyo, Japan), according
to the manufacturer's instruction. The first level of screening
based on the search for the most frequent mutations using the
commercial kit (Inno-Lipa CFTR19, Inno-Lipa CFTR17+
TnUpdate, Inno-Lipa CFTR-Italian Regional — Innogenetics,
Ghent, Belgium) identified the F508del mutation in heterozy-
gous status.
In order to detect rearrangements in the CFTR gene, the 27
exons were screened using the multiplex ligation probe amplifi-
cation (MLPA) assay based on the commercial Kit_SALSA P091
B1 CFTR MALPA Kit, according to the manufacturer's protocol
(MRC Holland, Amsterdam, Holland).
This assay, performed on the patient and her parents, showed
the presence of a large duplication, spanning from exon 6b to
exon 16 [Fig. 2].eferred to with 6b′, 7′, etc.
s F8f (located on exon 15) and 14R (located on exon 14b) on a 1.5% agarose gel.
er used is 50 bp ladder (Invitrogen).
xon 7. The image shows the junction between the beginning of the duplication
Fig. 2. MLPA results analysed by Coffalyser software . The histogram shows the duplication of exons 6b–16. The ratio values including 0.75–1.3 indicate a wild type
expression; ratio values lower than 0.75 suggest a deletion whilst values higher than 1.3 indicate a duplication. The probe 07-116.6 CFTR exon 10 (F508del) is normal
because the patient is heterozygous for the F508del.
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sequencing of coding regions, using the ABI 3130-XL system
(Applied Biosystems, Foster City, CA); the sequences were
compared with the wild-type CFTR nucleotide sequence using
Seqscape software (Applied Biosystems).2.3. RNA analysis
Nasal epithelial cells of the CF parent who does not carry the
c.1521_1523delCTT mutation (F508del) were obtained for
RNA analysis. RNA extraction and cDNA synthesis were
carried out using standard protocols. RNA was extracted by a
guanidinium isothiocyanate/phenol method (RNAZOL, Invi-
trogen Life Technologies, Groningen, The Netherlands) and
then subjected to digestion with RNase-free DNase I (Promega
GmbH, Mannheim, Germany). One μg of the total RNA was
reverse transcribed using hexanucleotide primers and high
capacity cDNA Archive kit (Applied Biosystems).
The cDNAwas amplified by PCR in six overlapping fragments
spanning the entire gene using FastStart Taq DNA Polymerase
(Roche) [7]. The PCR thermal cycling conditions are as follows:
initial denaturation at 95 °C for 6 min; 30–36 cycles of 95 °C for
30 s, annealing at 60 °C for 1 min and extension at 72 °C for 2 min
followed by a final extension at 72 °C for 8 min. The PCR was
tested by running 5 μl of the product on a 1.5% agarose gel in order
to identify large deletion/insertion and the product of possiblealternative splicing. For the patient's father, suspected of harbour-
ing the duplication, we designed two different PCR, performed on
cDNA samples, using primers F12f (5′-TTTAGGGGAAGTCAC-
CAAAGCAG-3′) and B15R (5′-GGGAAGCACAGATAAAAA-
CACCAC-3′) to identify the specific upstream junction fragment,
and primers F8f (5′-CTTGGAAACACTCCTCTTCAA-3′) and
B19R (5′-CCAACTCTTCCTTCTCCTTCTCCTG-3′) to screen
for the downstream junction fragment [7]. The corresponding
amplified products (705 bp, 739 bp) were used for DNA
sequencing verification.
Furthermore, to confirm the putative rearrangement, we
performed a long PCR amplification using a 5′ forward primer
F8f (5′-CTTGGAAACACTCCTCTTCAA-3′) and a 3′ reverse
primer 14R (5′-ACCTCTGCCAGAAAAATTAC-3′) and suc-
cessfully amplified a fragment of 2166 bp from theRNAsample of
the parent, but not from samples not harbouring the duplication [7].2.4. Genome-wide array analysis
Genome-wide array-CGH was performed using the Agilent
105A chip (Agilent Technologies, Santa Clara, CA) according
to the manufacturer's protocol. In brief, 500 ng of patient and
reference DNAs were double-digested with RsaI and AluI
(Promega, Madison, WI) for 2 h at 37 °C and labelled with Cy5-
dUTP and Cy3-dUTP respectively. After column purification,
labelled DNAs were combined, denaturated, pre-annealed with
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and hybridised at 65 °C for 40 h. After two washing steps,
images of the arrays were acquired with the Agilent scanner and
analysed with the Feature Extraction software (v10.5). A
graphical overview of the results was obtained with DNA
Analytics software (v4.0) [8].
2.5. Software used in data analysis
Three software and data processes were used in the data
analysis:
RepeatMasker programme is used for screening DNA
sequences in FASTA format; it finds interspersed repeats and
low complexity DNA sequences.
RECON is one of the most widely used software that imple-
ments de novo technology in identifying repetitive elements.
Clustal W is a general purpose multiple alignment programme
for DNA or protein sequences.
2.6. Nomenclature of CFTR mutations
The rearrangement described in this report is submitted to CF
Mutation Database as c.(?_744)_(2988_?)dup, in agreement with
the HGVS nomenclature (http://www.hgvs.org/mutnomen/); the
A of the ATG translation start codon is numbered +1.
3. Results
After an extensive DNA sequencing, the second mutation
was still unknown. MLPA technique detected a duplication
spanning in the region from exons 6b–16 both in the patient and
her father. The exact breakpoint of the duplication, however,
was not identified. Nasal epithelial cells of the father were
obtained for RNA analysis to confirm this putative rearrange-
ment. Theoretically, the duplication would lead to the
generation of a CFTR RNA containing exon 16 followed by
exon 6b; to confirm this putative rearrangement, we performed
a long PCR with a forward primer located on exon 15 and a
reverse primer on exon 14b. The amplification of this fragment
of 2166 bp provided a further confirmation for the presence of
this large duplication in the patient's RNA (Fig. 1B).
The rearrangement c.(?_744)_(2988_?)dup produces an
alternative mRNA population that is 2244 bp longer than
normal mRNA product.
The duplication is predicted to cause an out of frame addition
of eight amino acids (R S E S W E D Q) after codon Q996 of
exon 16, followed by a TGA stop codon. This would lead to the
production of a truncated CFTR protein containing the first
transmembrane domain (TM1), the first nucleotide binding
domain 1 (NBD1) and the regulatory domain, with a loss of the
remainder of the protein.
Arrays were performed using the Agilent array 180K platform
according to the manufacturer's protocol [9]. The patient showed
to have a duplication of about 70 kb (proximally: last normal
oligo 116,948,976 Mb, first duplicated one 116,963,849 Mb;
distally: last duplicated oligo 117,030,994 Mb, first normal one117,039,020 Mb) harbouring no less than 9 exons when
considering the internal edges of the duplication.
4. Discussion
Several comprehensive studies have been published describ-
ing the detection of various large rearrangements in the CFTR
gene. CFTR rearrangements account for around 2% of CF
alleles in the Italian population [5]. However, very few
duplications have been identified, and very recently the
breakpoints of the same deletion/duplication have been
characterised using CGH array [10,11,6].
We report here the detection and characterisation of a large
duplication, previously submitted to CF Mutation Database
(23/09/2010) by Pepermans et al., who identified the molecular
defect in a 14 year old Brazilian girl with a classical CF
phenotype. Our case is a one year old Caucasian female CF
patient, harbouring the F508del on the other allele, maternally
inherited. Interestingly, both the patients are heterozygous for
the F508del and show the same severe CF phenotypes
(pancreatic insufficiency and recurrent respiratory infections).
In particular, this large duplication was identified by MLPA
after extensive DNA sequencing of the promoter, the 27 CFTR
exons and flanking intronic regions had failed to identify a
second mutation.
To characterise this large duplication in greater detail, we
have applied different technologies and have defined our
strategy for analysing rearrangements.
The abnormal MLPA profile, identified in the CF patient and
in her father, was characterised by two alternative methods.
First, we used the mRNA approach to evaluate the transcript
profile [10]. Nasal epithelial cells of the father were obtained for
RNA analysis, which showed that this duplication produces an
abnormal transcript population with an out of frame addition of
2244 nucleotides which generates the aberrant product and
leads to the insertion of 8 amino-acid residues in the protein,
followed by a stop codon.
The CFTR protein produced by this anomalous transcript
should be truncated soon after exon 16. The stop signal is
located in the nucleotide binding domain region (NBD2) of the
protein and can lead to the formation of a non-functioning
protein.
We attempted to identify the mechanism behind the
duplication. We scanned the regions flanking the breakpoints
of the duplication in IVS6a and in IVS16 for repetitive
sequences and ALU repeats to identify a possible mechanism
for occurrence of this duplication.
Institute for Systems Biology RepeatMasker software (http://
www.repeatmasker.org) and RECON were used to scan for
repetitive elements [7,12,13]. The software identified two
elements of the SINE group and one simple repeat in IVS6a,
whereas 3 SINE, 2 LINE, elements were detected, as well as one
low complexity repeat, in IVS16. The alignment of these Alu
elements and IVS16 did not show sufficient homology to allow
for a homologous recombination event to occur.
To explore the molecular causes of this large rearrangement
in greater detail, we performed a multiple alignment of IVS6a
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that in the entire region of IVS6a, and from 127972 to 129194 in
the IVS16, there is a high sequence homology, in particular, for
231 bp, the mismatch does not exceed the 49 bases; this strong
sequence homology might promote the recombination event
identified in our patient.
In addition to the comprehensive and quick characterisation
of this new duplication, we have used array-CGH technology
which provides both high-resolution and sensitivity to charac-
terise copy-number variations [16,11]. The analysis showed a
duplication of about 70 kb (proximally: last normal oligoFig. 3. Detection by genomic CGH array of the duplication of exons 6b–16 in the C
116,948,976 Mb, first duplicated one 116,963,849 Mb; distally: last duplicated oligo
exons when considering the internal edges of the duplication.116,948,976 Mb, first duplicated one 116,963,849 Mb; distally:
last duplicated oligo 117,030,994 Mb, first normal one
117,039,020 Mb) harbouring no less than 9 exons when
considering the internal edges of the duplication (Fig. 3).
In summary, in this report we suggest a wide methodological
approach as a routine diagnostic analysis of the CF alleles
unknown after extensive DNA sequencing. The abnormal
MLPA profile can be validated by two alternative methods:
array CGH represents a high-resolution and sensitive technol-
ogy to characterise copy number variations, otherwise RT-PCR
performed on cDNA obtained by nasal brushing allows us toFTR gene. The duplication involves about 70 kb (proximally: last normal oligo
117,030,994 Mb, first normal one 117,039,020 Mb) harbouring no less than 9
417L. Costantino et al. / Journal of Cystic Fibrosis 10 (2011) 412–417evaluate the specific transcript profile [10]. In this way, it would
be possible to maximise mutant allele detection rates, with
evident positive implications for the genetic counselling of CF
patients and their families.
Since array-CGH is an expensive procedure for diagnostic
purposes, we suggest to use it only in particular conditions: a)
identification of uncharacterised rearrangements; b) patient age
over ten years (availability of nasal brushing).
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